MINIPRESS XL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Minipress Xl, and when can generic versions of Minipress Xl launch?
Minipress Xl is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in MINIPRESS XL is prazosin hydrochloride. There are seventeen drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the prazosin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Minipress Xl
A generic version of MINIPRESS XL was approved as prazosin hydrochloride by TEVA PHARMS on September 12th, 1988.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MINIPRESS XL?
- What are the global sales for MINIPRESS XL?
- What is Average Wholesale Price for MINIPRESS XL?
Summary for MINIPRESS XL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 117 |
| Clinical Trials: | 27 |
| Patent Applications: | 1,782 |
| DailyMed Link: | MINIPRESS XL at DailyMed |
Recent Clinical Trials for MINIPRESS XL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Yale University | Phase 1/Phase 2 |
| University of Washington | Phase 4 |
| Johns Hopkins University | Phase 2 |
US Patents and Regulatory Information for MINIPRESS XL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | MINIPRESS XL | prazosin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019775-001 | Jan 29, 1992 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer | MINIPRESS XL | prazosin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019775-002 | Jan 29, 1992 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MINIPRESS XL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | MINIPRESS XL | prazosin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019775-002 | Jan 29, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | MINIPRESS XL | prazosin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019775-001 | Jan 29, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | MINIPRESS XL | prazosin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019775-002 | Jan 29, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | MINIPRESS XL | prazosin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019775-002 | Jan 29, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | MINIPRESS XL | prazosin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019775-001 | Jan 29, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | MINIPRESS XL | prazosin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019775-002 | Jan 29, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MINIPRESS XL
See the table below for patents covering MINIPRESS XL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Norway | 146499 | ⤷ Sign Up | |
| Switzerland | 669329 | ⤷ Sign Up | |
| Japan | S6043045 | ⤷ Sign Up | |
| United Kingdom | 2140687 | OSMOTIC DRUG DELIVERY SYSTEM | ⤷ Sign Up |
| U.S.S.R. | 644387 | METHOD OF OBTAINING CRYSTALLINE A-FORM OF 2-/4-(2-FUROYL)-PIPERAZIN-1-YL/-4-AMINO-6,7-DIMETHOXYQUINAZOLINEHYDROCHLORIDE | ⤷ Sign Up |
| Hong Kong | 30881 | NOVEL CRYSTALLINE FORMS OF PRAZOSIN HYDROCHLORIDE | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
